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Abstract UMPICMP-kinase (UK) from the slime mold 
Dictyostelium discoideum has been purified to high homogeneity 
and co-crystallized with the bisubstrate inhibitor P’-(adenosine 
5’)-P5-(uridine S)-pentaphosphate (UP,A). UP,A binds to UK 
with a dissociation constant (K,,) of 3 f 0.5 nM at 2S’C and pH 
7.5. This is some 50-fold tighter than the binding of P’,P’-(dia- 
denosine 5’)-pentaphosphate (AP5A, Kd = 160 f 15 nM). AP,A 
is a bisubstrate inhibitor that is specific for adenylate kinase. The 
crystals have the symmetry of the tetragonal space group P4,2,2 
or its enant!omorph P4,2,2: The unit cell dimensions are 
a = b = 78.5 A and c = 101.4 A. The crystals diffract to a Bragg 
spacing of 2.1 A. 
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substrates are products of both the de novo and the salvage 
pathways. We are interested in the specificity of UK,,,,, in 
relation to other monophosphate kinases such as adenylate 
kinase or guanylate kinase and therefore need to investigate the 
architecture of the active site, in particular the monophosphate 
binding site. The structure of UMP-kinase from yeast was 
solved recently [2]. However, comparative complementation 
analysis of enzymatic activity indicated that UKyeas, has differ- 
ent properties than UKdictr since it accepts AMP almost as well 
as UMP or CMP as the phosphate acceptor. It therefore has 
to be considered to be not specific for pyrimidine nucleotides 
[3]. Secondly, the crystallized protein contained two adenosine 
nucleotide molecules and not just one ATP or ADP at the 
donor site, which would be expected for a kinase that is highly 
specific for pyrimidines at the acceptor site. It thus appears that 
the enzyme referred to as UMP-kinase from yeast should be 
called an unspecific NMP-kinase. 
1. Introduction 
Nucleoside monophosphate kinases (ATP: NMP phospho- 
transferases) catalyze the reversible transphosphorylation be- 
tween nucleoside triphosphates and nucleoside mono- 
phosphates. The best studied enzyme of this class is adenylate 
kinase (EC 2.7.4.3; AK) which catalyzes the phosphoryl trans- 
fer from the donor ATP to the acceptor molecule AMP. 
Whereas AK is highly specific for AMP as acceptor molecule, 
UMPICMP-kinase from the slime mold Dictyostelium discoi- 
deum (EC 2.7.4.14; UKdlcty) appears to accept both UMP and 
CMP as acceptors [l] and thus belongs to the group of pyrim- 
idine monophosphate kinases. 
We report here the crystallization of UK,,,,, with the bisub- 
strate inhibitor UP,A at its active site. We show by fluorescence 
measurements that UK,,,,, binds UP,A much tighter than 
AP,A, the bisubstrate inhibitor that is specific for adenylate 
kinases [4,5]. Determination of the crystal structure of this 
complex should enable us to answer the question of how UMPI 
CMP kinase achieves its specificity for pyrimidine nucleotides. 
2. Materials and methods 
2.1. Preparation of the bisubstrate inhibitor UP,A 
The bisubstrate inhibitor UP,A was prepared from AP, and UMP 
according to the method of Feldhaus et al. [5]. 
Pyrimidine kinases occupy a strategic position in the biosyn- 
thesis of pyrimidine nucleotides, since their phosphate acceptor 
2.2. Protein expression and purification 
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UMP/CMP kinase from Dictyostelium discoideum was expressed in 
E. coli as described [l]. 50 g cells were lysed with 300 mg lysozyme 
(Serva) in 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 20 mM DTE and 
0.04% (v/v) sodium azide. Subsequently, cell debris was removed as 
described [6]. The crude extract was applied to a blue Sepharose pseudo 
affinity column of 7 x 18 cm (bed volume of 700 ml). The column was 
equilibrated with the same buffer as described above. The flow rate was 
200450 ml/h. The column was washed with 2 vol. of the buffer. Most 
kinases from E. coli, such as adenylate kinase, were removed with a 
washing step of 1.3 I buffer that contained 0.25 M NaCl. 
UMP/CMP kinase from Saccharomyces cerevisiae. AK, adenylate ki- UMP/CMP kinase was eluted with 1 M NaCl (1 1) at a flow rate of 
nase (EC 2.7.4.3); AP,A, Pl,PS-(diadenosine-5’)-pentaphosphate; 100 ml/h. The eluate (1 g protein total) was dialyzed three times against 
UP,A, Pl-(adenosine 5’)-P5-(uridine 5’)-penta phosphate; mAP,Am, 10 1 of 25 mM Tris-acetate, pH 8.3, 1 mM EDTA, 20 mM DTE and 
a,w-[di(-(3’ or 2’)-O-(N-methyl-anthraniloyl)adenosine-S-O-)]penta- 0.04% (v/v) sodium azide (chromatofocusing buffer). The sample at a 
phosphate; EDTA, ehtylenediamine-tetraacetate; Tris, tris(hydroxy- concentration of at most 10 mg/ml was applied at 30 ml/min to a 
methyl)aminomethane; DTE, dithioerythritol. chromatofocusing column of 1.7 x 60 cm (bed volume 140 ml) filled 
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with polybuffer exchanger 94 (Pharmacia). The column was equili- 
brated with 10 vol. of chromatofocusing buffer prior to the application 
of the sample. After washing the column with 600 ml of chromatofocus- 
ing buffer, UK was eluted at pH 6.5 with a gradient from pH 8.3 to 5.0 
using 1.4 I of polybuffer. Adenylate kinase from E. coli elutes at pH 5.2 
and therefore this step is efficient in removing residual amounts of this 
enzyme. After dialysis against concentrated ammonium sulfate solution 
the urecioitate was redissolved in 6 ml s-buffer (50 mM Tris-HCI, oH 
7.4, ‘5 mM MgCIZ, 20 mM DTE and 0.04% sodium azide). Aliquots of 
2 ml of this concentrated protein solution were applied to a Superdex 
75 size exclusion column (Pharmacia) at 1 ml/min with s-buffer (see 
above). The protein concentration was determined according to 
Bradford [7] with bovine serum albumin as the standard protein. 
2.3. Protein crystallization 
A I : 1 complex of UK,,,,, and UP,A was prepared by mixing UK,,,,, 
and UP,A at a 1: 1 ratio. The protein was concentrated to 20 mg/ml 
in a centricon 10 centrifugation chamber (Amicon). Crystals of the 
UK:UP,A complex were grown at room temperature with 
the hanging drop method [8]. Equal volumes of concentrated protein 
nucleotide solution and a solution of 28% (w/v) polyethylene glycol 
3350 (Sigma), 100 mM Tris-HC], pH 8.8, 200 mM MgC12. 0.04% so- 
dium azide, 20 mM DTE were mixed and equilibrated against a reser- 
voir of the same composition but without protein or nucleotide. DTE 
is not essential for crystallization. 
3. Results and discussion 
3.1. Binding meusurements 
To learn how specific UKdicty is for UP,A, we measured the 
dissociation constant of UP,A and compared it to that of AP,A 
which is the bisubstrate inhibitor specific for adenylate kinases 
[4,5]. Binding of the fluorescent bisubstrate inhibitor mAP,Am 
[9] to UK,,,,, resulted in an increase in fluorescence intensity of 
200% at 360 nm excitation wavelength and 440 nm emission 
wavelength. The dissociation constant for mAP,Am was deter- 
mined as described [9] and is 154 nM. The dissociation con- 
stants of AP,Am and UP,A were determined in a competition 
experiment with mAP,Am [9] to be 160 f 15 nM for AP,A and 
3 t 0.5 nM for UP,A. All equilibrium experiments were per- 
formed at 25°C 50 mM Tris-HCl, pH 7.5, 1.6 mM MgCl,, 100 
mM KC1 and 20 mM DTE. It has been noted that the catalytic 
activity of UMP-kinases is highly dependent on the presence 
of a reducing agent such as DTE [lo] and we also found the 
presence of 20 mM DTE to be necessary to gain full catalytic 
activity. In conclusion, UK,,,,, is specific for UP,A. 
3.2. Protein crystallization 
Crystals grew within 335 days to a typical size of 
500 x 600 x 600pm3. For biochemical analysis the crystals were 
washed several times with artificial motherliquor which did not 
contain protein or nucleotide. Then the crystals were dissolved 
and subjected to SDS-PAGE [l 11. The crystals contained UK 
with the expected apparent mass of 25 kDa, showing that deg- 
radation had not occurred. Crystals treated the same way as 
described above but analyzed with a C,, reverse-phase column 
were found to contain the nucleotide UP,A. 
3.3. Collection of X-ray data 
Crystals were mounted in thin-walled glass capillaries. Two 
native datasets were collected using an Elliot GX13 rotating 
anode (CuK,) as the source of X-rays, a modified rotation 
camera and a Siemens/Nicolet area detector. The crystals dif- 
fract to 2.1 A resolution and are very stable in the X-ray beam. 
The determination of the space group symmetry and of the unit 
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Fig. 1. The displacement of the fluorescently labeled bisubstrate inhib- 
itor a,w-[di(-(3’ or 2’)-O-(N-methyl-anthraniloyl)adenosine-5’-O-)]pen- 
taphosphate (mAP,Am) by the bisubstrate inhibitors UP,A (0) or 
AP,A (0). The dissociation constant of UP,A was calculated as 3 + 0.5 
nM and that of AP,A as 160 ? 15 nM (see text). 600 ~1 of titration 
buffer contained 0.4 PM of the fluorescent bisubstrate inhibitor analog 
mAP,Am, 0.4 FM UK, 1.6 mM MgCl,, 50 mM Tris, pH 7.5, 100 mM 
KCl, 10 mM DTE at 25°C. Signal was the decrease in the intensity of 
the emission of mAP,Am at/E = 440 nm. The excitation wavelength was 
360 nm. 
cell parameters was performed with an extended version of the 
computer program XDS [12]. The crystals belong to the tetra- 
gonal space group P4,2,2 or the enantiomorphous space group 
P4,2,2 with unit cell dimensions of a = b = 78.5 A and c = 
100.4 A. 
Although density measurements of UK: UP,A crystals in a 
CCl,/Xylol density gradient suggest two molecules per asym- 
metric unit (the density is 1.27 g/cm3), corresponding to a V, 
of 1.8 A’/Da (28% solvent content) non-crystallographic sym- 
metry could not be detected unequivocally by self rotation 
studies. Structure determination will have to reveal the actual 
number of UK : UP,A molecules per asymmetric unit. 
Initial attempts to solve the structure by molecular replace- 
ment with known structures of adenylate kinase from E. coli 
or pig muscle (AKl) failed. We are currently collecting datasets 
with heavy atom derivatives. 
In conclusion, determination of the structure of the 
UK,+:UPSA complex should reveal how this type 
of NMP kinase gains specificity for the pyrimidine phosphate 
acceptor. Specifically, the comparison with the structure of the 
UK : AP,A complex is very promising, since it crystallizes in the 
same space group and with virtually identical cell dimensions, 
so that any differences in the mode of binding of AP,A should 
be attributable to the specificity of the nucleotide binding 
pocket. 
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